A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Healthy; Pneumococcal Infections

Treatments: Biological: V110, pneumococcal vaccine polyvalent

Study type: Interventional

Funder types: Industry

Identifiers

NCT00127153

2005_039

V110-013

Details and patient eligibility

About

The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.

Sex: All

Ages: 20 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males and females in good health, ages 20-40, with no history of pneumococcal vaccination

Exclusion criteria

• Subjects with a recent febrile illness
• Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chemotherapy, including long-term corticosteroid therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind